As of 2025-12-12, the EV/EBITDA ratio of Flexion Therapeutics Inc (FLXN) is -7.43. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FLXN's latest enterprise value is 581.19 mil USD. FLXN's TTM EBITDA according to its financial statements is -78.25 mil USD. Dividing these 2 quantities gives us the above FLXN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.4x - 15.1x | 15.0x |
| Forward P/E multiples | 20.1x - 28.6x | 23.1x |
| Fair Price | (93.89) - (72.28) | (89.31) |
| Upside | -460.7% - -377.7% | -443.2% |
| Date | EV/EBITDA |
| 2025-12-12 | -7.42 |
| 2025-12-11 | -7.43 |
| 2025-12-10 | -7.43 |
| 2025-12-09 | -7.41 |
| 2025-12-08 | -7.41 |
| 2025-12-05 | -7.42 |
| 2025-12-04 | -7.42 |
| 2025-12-03 | -7.42 |
| 2025-12-02 | -7.41 |
| 2025-12-01 | -7.40 |
| 2025-11-28 | -7.41 |
| 2025-11-26 | -7.41 |
| 2025-11-25 | -7.40 |
| 2025-11-24 | -7.36 |
| 2025-11-21 | -7.30 |
| 2025-11-20 | -7.27 |
| 2025-11-19 | -7.30 |
| 2025-11-18 | -7.29 |
| 2025-11-17 | -7.29 |
| 2025-11-14 | -7.32 |
| 2025-11-13 | -7.31 |
| 2025-11-12 | -7.36 |
| 2025-11-11 | -7.37 |
| 2025-11-10 | -7.36 |
| 2025-11-07 | -7.32 |
| 2025-11-06 | -7.32 |
| 2025-11-05 | -7.33 |
| 2025-11-04 | -7.32 |
| 2025-11-03 | -7.33 |
| 2025-10-31 | -7.35 |
| 2025-10-30 | -7.34 |
| 2025-10-29 | -7.36 |
| 2025-10-28 | -7.38 |
| 2025-10-27 | -7.38 |
| 2025-10-24 | -7.37 |
| 2025-10-23 | -7.35 |
| 2025-10-22 | -7.34 |
| 2025-10-21 | -7.35 |
| 2025-10-20 | -7.35 |
| 2025-10-17 | -7.33 |
| 2025-10-16 | -7.31 |
| 2025-10-15 | -7.34 |
| 2025-10-14 | -7.32 |
| 2025-10-13 | -7.31 |
| 2025-10-10 | -7.27 |
| 2025-10-09 | -7.31 |
| 2025-10-08 | -7.33 |
| 2025-10-07 | -7.34 |
| 2025-10-06 | -7.35 |
| 2025-10-03 | -7.35 |